BIODOL THERAPEUTICS
Fabien Granier has a diverse work experience in various roles and industries. Fabien co-founded BIODOL Therapeutics in 2014 and currently serves as the CEO. The company focuses on developing compounds for the treatment of chronic neuropathic pain. Fabien has also co-founded Colcom in 2006, a company that produces and markets nanomolecules internationally. Prior to that, they worked as a Projects Manager at Languedoc Roussillon Incubation from 2002 to 2006, where they provided coaching and support to startup creators. Fabien was also involved in a project called TIC from 2001 to 2002, which aimed to create a LinkedIn-like platform. Although this project did not result in an actual enterprise, Fabien gained valuable experience in human relationships, management, administration, and business.
Fabien Granier pursued their education from 1997 to 2000 at the University of Montpellier, where they successfully completed their Doctor of Philosophy (PhD) in Quantum Chemistry.
This person is not in any teams
BIODOL THERAPEUTICS
Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key player for triggering and maintaining the chronic neuropathic pain (NP) state. New findings from Biodol Therapeutics' academic partnership (CyrilRivat and Jean Valmier at the INSERM Institute for Neurosciences in Montpellier) also demonstrated that FLT3 inhibition increases the potency of opioids for their analgesic effect, and hereby reduces their safety risks, especially addiction risk, which will help fighting the Opioid Crisis. The development of extracellular inhibitors of the FLT3 receptor, is a proprietary and key approach developed by Biodol Therapeutics.